drugset / Trial / NCT03638193
Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Unknown
10 enrolled
Shenzhen BinDeBio Ltd.
The First Affiliated Hospital with Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study in which pancreatic cancer patients receive a immunotherapy with CART-meso cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells lentivirally transduced to express anti-mesothelin scFv fused to TCRζ and 4-1BB costimulatory domains.The lymphodepletion with cyclophosphamide may prolong the persistence of CART cells.
Timeline
- Start
- 2018-07-11
- Primary completion
- 2022-02-01
- Completion
- 2022-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-meso cells | Cell therapy | 1e+07 unknown | Intravenous |
| Subject | CART-meso cells | Cell therapy | 1e+08 unknown | Intravenous |